Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy

Supportive Care in Cancer

Volumn 14, Issue 5, 2006, Pages 400-407

  Ripamonti, Carla ^a   Fagnoni, Elena ^a   Campa, Tiziana ^a   Brunelli, Cinzia ^a   De Conno, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer; Opioid administration; Oral morphine; Pain; Settings of care; Switching; Titration; Transdermal fentanyl

Indexed keywords

BUPRENORPHINE; CODEINE; FENTANYL; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; TRAMADOL;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; DRUG SUBSTITUTION; DYSPHAGIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ITALY; MALE; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; FENTANYL; GUIDELINE ADHERENCE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; WORLD HEALTH ORGANIZATION;

EID: 33646444297     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0918-0     Document Type: Article

References (31)

1. World Health Organization (1986) Cancer pain relief. World Health Organization, Geneva, Switzerland
2. World Health Organization (1996) Cancer pain relief, 2nd edn. World Health Organization, Geneva, Switzerland
3. World Health Organization (1999) Model list of essential drugs (EDL), 11th edn. Available at http://www.who.int/medicines/organization/par/edl/ infed111group.litml
4. Hanks GW, De Conno F, Ripamonti C et al (Expert Working Group of the European Association for Palliative Care) (1996) Morphine in cancer pain: modes of administration. BMJ 312:823-826
5. Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84(5):587-593
6. Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994) Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94-0592, March, Rockville
7. Gourlay GK (2001) Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2:165-172
8. Chinellato A, Terrazzani G, Walley T, Giusti P (2003) Opioids in Italy: is marketing more powerful than the law? Lancet 362:78
9. De Conno F, Ripamonti C, Brunelli C (2005) Opioid purchases and expenditure in nine western European countries. "Are we killing off morphine?" Palliat Med 19:179-184
10. Radbruch L, Nauck F, Sabatowski R (2002) Germany: Cancer pain and palliative care - current situation. J Pain Symptom Manage 24(2):183-187
11. Kornik CA, Santiago-Palma J, Moryl N, Payne R (2003) Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 26(13):951-973
12. Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629-2638
13. Scottish Intercollegiate Guidelines Network (SIGN) (2000) Cancer pain guidelines. SIGN, Edinburgh
14. Gourlay GK, Kowalski SR, Plummer JL et al (1989) The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain 37:193-202
15. Korke W, de Stoutz N, Morant R (1996) Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 11:139-146
16. Portenoy RK, Southam MA, Gupta SK et al (1993) Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics. Anesthesiology 78:36-43
17. Varvel JR, Shaker SL, Hwang SS et al (1989) Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70:928-934
18. Holley FO, Van Steennis C (1988) Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate IV and transdermal delivery: Br J Anaesth 60:608-613
19. Gourlay GK, Kowalski SR, Plummer JL et al (1990) The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 20:21-28
20. Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E, Vlahos L (2001) From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 21:2225-2230
21. Burza M, Ginobbi P, Fusco G, Laurenzi L, Tirelli W, Arcuri E (1998) Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 149(4):277-280
22. Van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WWA (2003) Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 19(6):457-469
23. Tawfik MO, Bryuzgin V and Kourteva G (FEN-INT-20 Study Group) (2004) Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 20(3):259-267
24. Vielvoye-Kerkmeer A, Mattem C, Uitendaal MP (2000) Transdermal fentanyl in opioid-naïve cancer patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naïve patients and a group using codeine. J Pain Symptom Manage 19:185-192
25. Janssen, LP (2005) Important drug warning. http://www.fda.gov/medwatch/ SAFETY/2005/duragesic_ddl.pdf
26. Megens A, Artois K, Vermeire J et al (1998) Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 15:253-257
27. Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life - the TTS-fentanyl Comparative Trial Group. J Pain Symptom Manage 13:254-261
28. Donner B, Zenz M, Tryba M et al (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64:527-534
29. Payne R, Mathias SD, Pasta DJ et al (1998) Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16:1588-1593
30. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (Expert Working Group the Research Network of EAPC) (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542-2554
31. Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14:111-119